EGFR stands for Epidermal Growth Factor Receptor. It’s a protein found on the surface of many cells throughout the body. EGFR plays a crucial role in regulating cell growth, division, and survival.
In the context of non-small cell lung cancer (NSCLC):
- EGFR Mutations: Certain mutations in the EGFR gene can lead to uncontrolled cell growth, promoting the development of lung cancer. These mutations are more common in certain populations, such as East Asians and never-smokers.
- Targeted Therapy: EGFR mutations are a significant target for treatment. EGFR tyrosine kinase inhibitors (TKIs) are a class of drugs specifically designed to block the activity of the mutated EGFR protein, inhibiting tumor growth and leading to significant improvements in survival for patients with EGFR-mutated NSCLC.
Key Points:
- EGFR is a protein involved in cell growth and survival.
- EGFR mutations are common in NSCLC, particularly in certain populations.
- EGFR TKIs are targeted therapies that effectively treat EGFR-mutated NSCLC.